Abstract
Treatment of acute leukemia has evolved rapidly over the past 10 years. Moreover, the role of hematopoietic stem cell transplantation (HSCT) in such treatments has been changing. With the refinement of molecular-targeted therapy and other new modalities, HSCT is no longer the only curative option for leukemia. Nowadays, HSCT is being incorporated into the comprehensive scheme of leukemia treatment and is being compared to other treatment options. This was made possible through the effort to decrease nonrelapse mortality associated with HSCT to levels comparable with those of other modalities. In this review, we will particularly focus on transplantation in patients with aggressive leukemia and graft failure and discuss the role of conditioning regimens for HSCT in the new era of targeted therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
